166 related articles for article (PubMed ID: 23250130)
1. Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario.
Marriott JJ; Mamdani M; Saposnik G; Gomes T; Manno M; O'Connor PW
Can J Neurol Sci; 2013 Jan; 40(1):67-72. PubMed ID: 23250130
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study.
Cameron E; Rog D; McDonnell G; Overell J; Pearson O; French DP
Mult Scler Relat Disord; 2019 Jan; 27():378-382. PubMed ID: 30500689
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
Oleen-Burkey M; Cyhaniuk A; Swallow E
J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877
[TBL] [Abstract][Full Text] [Related]
4. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
[TBL] [Abstract][Full Text] [Related]
5. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A
J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107
[TBL] [Abstract][Full Text] [Related]
6. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
7. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
Krysko KM; Graves J; Rensel M; Weinstock-Guttman B; Aaen G; Benson L; Chitnis T; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Rodriguez M; Rose J; Waltz M; Charles Casper T; Waubant E;
Neurology; 2018 Nov; 91(19):e1778-e1787. PubMed ID: 30333163
[TBL] [Abstract][Full Text] [Related]
8. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register.
Lepore V; Paletta P; Bosetti C; Santucci C; Ponzio M; Pupillo E; Leone MA; Bergamaschi R; Mosconi P;
Mult Scler Relat Disord; 2024 Jul; 87():105638. PubMed ID: 38713966
[TBL] [Abstract][Full Text] [Related]
9. Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
Reyes S; Suarez S; Allen-Philbey K; Yildiz Ö; Mathews J; Anjorin G; Edwards F; Jain C; Turner B; Marta M; Gnanapavan S; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Jun; 41():102024. PubMed ID: 32143179
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
11. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
13. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
14. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
[TBL] [Abstract][Full Text] [Related]
15. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.
Leblanc S; Roux J; Tillaut H; Le Page E; Leray E
Rev Neurol (Paris); 2021 Dec; 177(10):1250-1261. PubMed ID: 34253346
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
19. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
Higuera L; Carlin CS; Anderson S
J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
[TBL] [Abstract][Full Text] [Related]
20. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
